Table 3. Inflammatory markers assessments* at baseline and after intervention (6 weeks) according to experimental groups**.
| Control (n = 13) | Yacon flour (n = 13) | P inter | |||
|---|---|---|---|---|---|
|
| |||||
| Baseline | 6 weeks | Baseline | 6 weeks | ||
|
| |||||
| Adjusted mean ± SEM | Adjusted mean ± SEM | Adjusted mean ± SEM | Adjusted mean ± SEM | ||
| Leukocytes (mm3) | 6338.58 ± 474.68 | 6266.96 ± 538.22 | 6952.60 ± 334.45 | 6788.12 ± 423.70 | 0.804 |
| Neutrophils (mm3) | 3657.07 ± 363.34 | 3773.76 ± 466.87 | 3951.24 ± 351.18 | 3879.20 ± 317.55 | 0.560 |
| Lymphocytes (mm3) | 2355.27 ± 208.02 | 2094.36 ± 157.24 | 2448.14 ± 248.51 | 2424.11 ± 213.34 | 0.206 |
| Platelet (103/mm3) | 206.06 ± 131.85 | 198.58 ± 134.17 | 208.90 ± 170.23 | 216.19 ± 164.83 | 0.160 |
| Neutrophil/lymphocyte rate | 1.61 ± 0.21 | 1.81 ± 0.19 | 1.76 ± 0.24 | 1.63 ± 0.20 | 0.100 |
| Platelet/Lymphocyte rate | 91.20 ± 7.84 | 97.86 ± 8.22 | 91.02 ± 11.45 | 92.23 ± 11.56 | 0.443 |
| C reactive protein | 2.52 ± 0.84 | 2.58 ± 0.86 | 4.89 ± 1.07 | 5.23 ± 1.17 | 0.623 |
* Results were obtained analyzing fasting blood (complete blood count (leukocytes, lymphocytes, neutrophils and platelets) and plasma (CRP)) samples.
** Data are given as adjusted mean and SEM per treatment group. No significant difference occurred intra-group or between-groups (by generalized estimating equation model, p > 0.05). P inter: between-group comparisons at 6 weeks was adjusted for baseline.